Breast Cancer

Early HR+

View All

Early-Stage HR+ Breast Cancer treatment update on managing CDK4/6 inhibitor sequencing with expert physicians at OncUpdates.

Early HR+

01/09/2026

Ep. 4: Early-Stage HR-Positive Breast Cancer: Managing CDK4/6 Inhibitor Sequencing

Sara Hurvitz, MD, FACPSherry Shen, MDEleanora Teplinsky, MDRahul Gosain, MD, MBARohit Gosain, MD

Liver toxicity research with expert doctors discussing risk stratification and personalized adjuvant therapy in early-stage HR+ breast cancer treatment.

Early HR+

01/07/2026

Ep. 3: Liver Toxicity, Risk Stratification, and Personalized Adjuvant Therapy in Early-Stage HR-Positive Disease

Sara Hurvitz, MD, FACPSherry Shen, MDEleanora Teplinsky, MDRahul Gosain, MD, MBARohit Gosain, MD

1. Expert panel on practical guidance for Ribociclib and Abemaciclib in adjuvant cancer therapy, featuring leading oncologists discussing advanced treatment strategies.

Early HR+

01/05/2026

Ep. 2: Practical Guidance for Ribociclib and Abemaciclib in the Adjuvant Setting

Sara Hurvitz, MD, FACPSherry Shen, MDEleanora Teplinsky, MDRahul Gosain, MD, MBARohit Gosain, MD

Adjuvant Ribociclib in early-stage HR+ breast cancer clinical insights featuring expert doctors and research leaders.

Early HR+

01/03/2026

Ep. 1: Adjuvant Ribociclib in Early-Stage HR-Positive Breast Cancer: Clinical Insights

Sara Hurvitz, MD, FACPSherry Shen, MDEleanora Teplinsky, MDRahul Gosain, MD, MBARohit Gosain, MD

Adjuvant CDK4/6 therapy in early HR+ breast cancer, featuring Dr. Eleonora Teplinsky, Dr. Sherry Shen, Dr. Rahul Gosain, Dr. Sara Hurwitz, and Dr. Rohit Gosain, with clinical insights and expertise.

Early HR+

12/20/2025

Adjuvant Ribociclib and Abemaciclib in Early HR+ Breast Cancer (Full Video)

Eleanora Teplinsky, MDSara Hurvitz, MD, FACPSherry Shen, MDRahul Gosain, MD, MBARohit Gosain, MD

Metastatic HR+

View All

1. OncUpdates presentation on Ribociclib and oral SERDs in high-risk cancer disease featuring expert oncologists and researchers.

Metastatic HR+

01/14/2026

Ep. 4: Ribociclib and the Evolving Role of Oral SERDs in High-Risk Disease

Laura Huppert, MDKomal Jhaveri, MD, FACPHeather McArthur, MDHope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD

OncUpdates panel discussing Abemaciclib vs Ribociclib for clinical decision-making and improving quality of life in cancer patients, featuring expert oncologists Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Laura Huppert, Dr. Komal Jhaveri, Dr. Hope Rugo, and Dr. Heather McArthur.

Metastatic HR+

01/12/2026

Ep. 3: Abemaciclib vs Ribociclib: Clinical Decision-Making for Quality of Life

Laura Huppert, MDKomal Jhaveri, MD, FACPHeather McArthur, MDHope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD

1. OncUpdates panel discussing metastatic HR+ breast cancer and CDK4/6 inhibitor treatment options with leading oncology experts.

Metastatic HR+

01/10/2026

Ep. 2: Metastatic HR-Positive Breast Cancer: Choosing the Right CDK4/6 Inhibitor

Laura Huppert, MDKomal Jhaveri, MD, FACPHeather McArthur, MDHope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD

OncUpdates medical experts discussing clinical insights on optimizing Ribociclib, Abemaciclib, and Palbociclib for cancer treatment.

Metastatic HR+

01/06/2026

Ep. 1: Clinical Insights: Optimizing Ribociclib, Abemaciclib, and Palbociclib Use in Metastatic HR-Positive Breast Cancer

Laura Huppert, MDKomal Jhaveri, MD, FACPHeather McArthur, MDHope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD

1. Expert panel discusses CDK4/6 inhibitors in metastatic breast cancer at OncUpdates, featuring leading oncologists and researchers.

Metastatic HR+

12/31/2025

CDK4/6 Inhibitor Selection in HR+ Metastatic Breast Cancer (Full Video)

Laura Huppert, MDKomal Jhaveri, MD, FACPHeather McArthur, MDHope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD